As part of our ongoing effort to bring you reports of interesting new studies, we have added a review of the ELEVATE-R/R study looking at Acalabrutinib versus Ibrutinib for previously treated CLL.
Independent expert commentary is provided by Dr Georgina Hodges, a clinical haematologist in Geelong, Victoria.
Please login below to download this issue (PDF)